Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the ...
TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...
A number of neurodegenerative diseases of the brain are characterized by inclusions within neurons that are comprised of aggregated fibrils of hyperphosphorylated tau protein. These disorders, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback